Literature DB >> 31445232

Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT2C) receptor agonist without 5-HT2B agonism.

Guiping Zhang1, John D McCorvy2, Sida Shen3, Jianjun Cheng4, Bryan L Roth2, Alan P Kozikowski5.   

Abstract

A new series of fluorinated 5-HT2C agonists were designed and synthesized on the basis of our previous work on 2-phenylcyclopropylmethylamines as a potential approach for the treatment of central nervous system disorders. Key fluorinated cyclopropane moieties were constructed through transition metal catalyzed [2 + 1]-cycloaddition of aromatic vinyl fluorides, and the absolute stereochemistry of the representative compound (-)-21a was established. Functional activity measuring calcium flux at 5-HT2 receptors reveals high potency for compounds (+)-21a-d. In particular, (+)-21b had no detectable 5-HT2B agonism and displayed reasonable selectivity against 5-HT2A. Molecular docking studies were further performed to explain the compounds' possible binding poses to the 5-HT2C receptor. Published by Elsevier Masson SAS.

Entities:  

Keywords:  5-HT(2B) receptor; 5-HT(2C) receptor; Agonist; Asymmetric synthesis; Fluorinated cyclopropane

Mesh:

Substances:

Year:  2019        PMID: 31445232      PMCID: PMC6815260          DOI: 10.1016/j.ejmech.2019.111626

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  22 in total

1.  Drugs and valvular heart disease.

Authors:  Bryan L Roth
Journal:  N Engl J Med       Date:  2007-01-04       Impact factor: 91.245

Review 2.  A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.

Authors:  Jose M Palacios; Angel Pazos; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

3.  Design and Discovery of Functionally Selective Serotonin 2C (5-HT2C) Receptor Agonists.

Authors:  Jianjun Cheng; John D McCorvy; Patrick M Giguere; Hu Zhu; Terry Kenakin; Bryan L Roth; Alan P Kozikowski
Journal:  J Med Chem       Date:  2016-10-25       Impact factor: 7.446

4.  Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.

Authors:  Jianjun Cheng; Patrick M Giguère; Oluseye K Onajole; Wei Lv; Arsen Gaisin; Hendra Gunosewoyo; Claire M Schmerberg; Vladimir M Pogorelov; Ramona M Rodriguiz; Giulio Vistoli; William C Wetsel; Bryan L Roth; Alan P Kozikowski
Journal:  J Med Chem       Date:  2015-02-10       Impact factor: 7.446

5.  Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.

Authors:  R B Rothman; M H Baumann; J E Savage; L Rauser; A McBride; S J Hufeisen; B L Roth
Journal:  Circulation       Date:  2000-12-05       Impact factor: 29.690

6.  Lorcaserin. In obesity: unacceptable risks.

Authors: 
Journal:  Prescrire Int       Date:  2014-05

7.  Crystal Structure of an LSD-Bound Human Serotonin Receptor.

Authors:  Daniel Wacker; Sheng Wang; John D McCorvy; Robin M Betz; A J Venkatakrishnan; Anat Levit; Katherine Lansu; Zachary L Schools; Tao Che; David E Nichols; Brian K Shoichet; Ron O Dror; Bryan L Roth
Journal:  Cell       Date:  2017-01-26       Impact factor: 41.582

8.  Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.

Authors:  Sung Jin Cho; Niels H Jensen; Toru Kurome; Sudhakar Kadari; Michael L Manzano; Jessica E Malberg; Barbara Caldarone; Bryan L Roth; Alan P Kozikowski
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

Review 9.  Molecular signatures of G-protein-coupled receptors.

Authors:  A J Venkatakrishnan; Xavier Deupi; Guillaume Lebon; Christopher G Tate; Gebhard F Schertler; M Madan Babu
Journal:  Nature       Date:  2013-02-14       Impact factor: 49.962

10.  Lorcaserin for the treatment of obesity? A closer look at its side effects.

Authors:  James J DiNicolantonio; Subhankar Chatterjee; James H O'Keefe; Pascal Meier
Journal:  Open Heart       Date:  2014-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.